Clinical Trial Update: Empagliflozin as a Novel Therapy in Refractory Ascites [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports empagliflozin as a novel therapy for refractory ascites in hepatic disease, with Phase 2 and Phase 3 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Hepatic Disease

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Alexandria University | Conditions: Ascites Hepatic | Phase 2, Phase 3 | Status: COMPLETED